HeyJaredAnnika Kim Constantino
- Indexed articles, last 90 days
- 30
- Latest publication
- Sep 30, 2026
- Outlet visibility, for CNBC
- Top 5K sites
- Earliest in this view
- Jul 8, 2026
Latest articles
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial (opens the original)
Read excerpt
Eli Lilly on Wednesday said its experimental combination regimen showed greater weight loss than a high dose of its top-selling drug, tirzepatide, alone in a mid-stage trial on patients with obesity and Type 2 diabetes. The combo therapy met the study's main goals in a population that typically struggles to lose weight. The results boost hopes that it could serve as an alternative blockbuster treatment option for people who didn't respond to or see the results they wanted on the current GLP-1 p
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study (opens the original)
Read excerpt
People who switched from obesity injections to Novo's new Wegovy pill continued to lose weight after three months, according to an analysis of real-world data the company presented on Wednesday. Real-world studies evaluate associations and can't determine causality. But the results suggest that the Wegovy pill may improve upon the initial weight loss people experience on blockbuster injections rather than simply maintain it. It also suggests that patients may not need to take weekly shots like
Trump administration removes around 760,000 Obamacare enrollments, alleging fraud (opens the original)
Read excerpt
The Centers for Medicare and Medicaid Services said on Tuesday it canceled roughly 315,000 Affordable Care Act marketplace enrollments covering about 760,000 people last month, alleging unauthorized enrollments, characterized by Vice President JD Vance as "rampant fraud." The enforcement action also involves verifying roughly 419,000 people to ensure they are legal U.S. residents and meet the income threshold requirements to receive benefits from the public exchanges of the ACA, also known as Ob
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs (opens the original)
Read excerpt
Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since Medicare coverage of obesity drugs launched in July, and 70% of those patients are on Lilly medicines. In an exclusive interview with CNBC, Ricks called the rollout of coverage "very encouraging" so far, saying its expansion of the broader GLP-1 market "is what we had hoped." His comments offer the latest metrics on how much the coverage is expanding access to the medicines, and who appears
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production (opens the original)
Read excerpt
Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking the drugmaker's Foundayo, as the company tries to catch up to a lead in the space established by rival Novo. In an exclusive interview, he said the company's share of the oral market is growing week over week. "We're confident long term" about Lilly's place in the pill segment, Ricks said, especially as the company plans to launch Foundayo in more international markets in the coming months. Ricks sp
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5K sites
For CNBC, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.